Glucagon-like peptide-1 receptor agonist versus other anti-diabetic agents on patients with prostate cancer undergoing androgen-deprivation therapy
Frontiers in Urology · 07.08.2026 · 6
DOI: 10.3389/fruro.2026.1855180 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Urology, online erschienen am 07.08.2026. Verfasst von Sheng-Chi Huang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Medicine, Chi Mei Medical Center, Tainan, Taiwan. Die Arbeit nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Patients with prostate cancer (PCa) undergoing androgen deprivation therapy (ADT) frequently develop cardiometabolic complications, particularly those with type 2 diabetes (T2D). Glucagon-like peptide-1 receptor agonists (GLP-1RAs) provide cardiovascular and renal benefits in diabetic populations, but comparative evidence with other glucose-lowering therapies in men receiving ADT remains limited. We conducted a retrospective cohort study using the TriNetX network. Adults with T2D and PCa undergoing ADT who received GLP-1RA, dipeptidyl peptidase-4 inhibitors (DPP-4is), or sodium–glucose cotransporter-2 inhibitors (SGLT2is) between January 2005 and December 2025 were included. Propensity score matching generated balanced cohorts for two comparisons: GLP-1RA versus DPP-4i and GLP-1RA versus SGLT2i. The primary outcome was all-cause mortality; secondary outcomes were major adverse cardiovascular events (MACEs), major adverse kidney events (MAKEs), and thrombotic events. After matching, 659 patients per group were included in the GLP-1RA versus DPP-4i comparison and 1,009 per group in the GLP-1RA versus SGLT2i comparison. Compared with DPP-4i, GLP-1RA use was associated with lower all-cause mortality (HR, 0.60; 95% CI, 0.46–0.79), MAKEs (HR, 0.63; 95% CI, 0.48–0.81), and thrombotic events (HR, 0.53; 95% CI, 0.32–0.89), whereas MACEs were similar (HR, 0.87; 95% CI, 0.63–1.12). Compared with SGLT2i, GLP-1RA use was associated with lower all-cause mortality (HR, 0.76; 95% CI, 0.59–0.99), whereas no significant differences were observed for MACEs, MAKEs, or thrombotic events. These neutral findings should be interpreted cautiously because the limited number of events may have reduced statistical power to detect modest between-group differences. In conclusion, among men with PCa receiving ADT and comorbid T2D, GLP-1RA use was associated with lower all-cause mortality than both DPP-4i and SGLT2i, with additional reductions in kidney and thrombotic events versus DPP-4i. GLP-1RAs may represent a favorable therapeutic option in this metabolically and vascularly vulnerable population. Prospective studies are warranted to confirm these associations and clarify the underlying mechanisms.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of General Medicine, Chi Mei Medical Center, Tainan, Taiwan.
- Division of Urology, Department of Surgery, Chi Mei Medical Center, Tainan, Taiwan.
- Department of General Medicine, Taipei Medical University Hospital, Taipei, Taiwan.
- Department of Nutrition, Chi Mei Medical Center, Tainan, Taiwan.
- Department of Public Health, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
- Department of Intensive Care Medicine, Chi Mei Medical Center, Tainan, Taiwan.
Zitieren
APA
Huang, S. C., Cheng, W. Y., Hou, C. Y., Wu, J. Y., Lai, C. C., & Tseng, W. H. (2026). Glucagon-like peptide-1 receptor agonist versus other anti-diabetic agents on patients with prostate cancer undergoing androgen-deprivation therapy. Frontiers in Urology, 6. https://doi.org/10.3389/fruro.2026.1855180
Vancouver
Huang SC, Cheng WY, Hou CY, Wu JY, Lai CC, Tseng WH. Glucagon-like peptide-1 receptor agonist versus other anti-diabetic agents on patients with prostate cancer undergoing androgen-deprivation therapy. Frontiers in Urology. 2026;6. doi:10.3389/fruro.2026.1855180
BibTeX
@article{Huang2026,
author = {Huang, Sheng-Chi and Cheng, Wan-Yu and Hou, Cheng-You and Wu, Jheng-Yan and Lai, Chih-Cheng and Tseng, Wen-Hsin},
title = {Glucagon-like peptide-1 receptor agonist versus other anti-diabetic agents on patients with prostate cancer undergoing androgen-deprivation therapy},
journal = {Frontiers in Urology},
year = {2026},
volume = {6},
doi = {10.3389/fruro.2026.1855180}
}
EUVIMED